anti-MUC1 CAR-T cells
/ Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 01, 2021
[VIRTUAL] Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer
(ESMO-GI 2021)
- P1/2 | "The efficacy of this unique combined therapy is currently being assessed. Our limited data indicate that the best achievable clinical outcome is SD meaning that the anticancer effect of current CART cells with PD-1 inhibition on solid tumours have a ceiling."
CAR T-Cell Therapy • Clinical • IO biomarker • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology • IL6 • MRI • PD-1
1 to 1
Of
1
Go to page
1